



ACC.15

TCT@ACC-12 | innovation in intervention

A2008
JACC March 17, 2015
Volume 65, Issue 10S

Valvular Heart Disease

ANTITHROMBOTIC THERAPY IN PATIENTS WITH AN INDICATION FOR ORAL ANTICOAGULATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT

Poster Contributions

Poster Hall B1

Sunday, March 15, 2015, 9:45 a.m.-10:30 a.m.

Session Title: Transcatheter Aortic Valve Replacement

Abstract Category: 40. Valvular Heart Disease: Clinical

Presentation Number: 1193-358

Authors: *Jeffrey Edward Rossi, Brian Bergmark, James McCabe, David Nemer, Andrew Noll, David Okada, Anant Vasudevan, Michael Davidson, Frederick Welt, Pinak Shah, Andrew Eisenhauer, Robert Giugliano, Brigham and Women's Hospital, Boston, MA, USA*

Background: Aspirin (ASA) + clopidogrel is recommended for 3-6 months following transcatheter aortic valve replacement (TAVR). Many patients undergoing TAVR also have an indication for oral anticoagulation (OAC). Antithrombotic regimens prescribed to these patients have not been well studied.

Methods: Chart review of all patients undergoing TAVR at Brigham and Women's Hospital between April 2009 and March 2014. Antithrombotic medications, comorbid conditions, and indications for OAC were assessed.

Results: Of 255 patients (mean age 81, 48% women), 169 (66%) had transfemoral TAVR. 131 (51%) patients had an indication for OAC pre-TAVR, 122 (48%) with atrial fibrillation (AF) and CHADS2 score ≥ 2 , 6 (2%) with DVT/PE and 3 (1%) with other indications. Of these patients, 92 (70%) were on OAC prior to the procedure. Complete baseline and discharge antithrombotic use is shown in the table. Of 153 patients with an indication for OAC post-TAVR (including 19 with new onset AF), 77 (51%) were bridged with parental anticoagulation after the procedure. Of 87 surviving patients on baseline OAC, 7 (8%) had OAC held after TAVR. Of 106 patients discharged on OAC, 89 (84%) were treated with ASA+OAC.

Conclusion: Antithrombotic regimens before and after TAVR are highly variable. At our institution, most patients on OAC prior to TAVR are discharged on ASA+OAC with half bridged with a parental anticoagulant. Prospective evaluation to determine the optimal antithrombotic regimen in this population is needed.

SAPT = ASA or P2Y12 antagonist, DAPT = ASA + P2Y12 antagonist, Triple = ASA + P2Y12 + OAC							
Admission Antithrombotic Regimen	Discharge Antithrombotic Regimen						
	SAPT	DAPT	OAC	SAPT+OAC	Triple	Died	TOTAL
None	4	16	0	4	1	5	30
SAPT	7	78	0	16	0	3	104
DAPT	1	21	0	4	1	2	29
OAC	0	1	2	21	7	2	33
SAPT+OAC	0	5	0	43	3	3	54
Triple	0	1	0	1	3	0	5
TOTAL	12	122	2	89	15	15	255